Stocklytics Platform
Exelixis
EXEL78
$36.80arrow_drop_down1.07%-$0.40
High Quality
EXEL78

$36.80

arrow_drop_down1.07%

Performance History

arrow_drop_up56.82%

(+$8.83 )

Stocklytics logo
Key Stats
Open$37.25
Prev. Close$37.20
EPS1.76
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
Market Cap$10.29B
PE Ratio20.91
LOWHIGH
Day Range36.74
37.71
52 Week Range18.64
39.99
Ratios
P/B Ratio4.83
Revenue$2.16B
Operating M. %28.84%
Earnings$521.26M
Earnings Growth %150.89%
EBITDA Margin %33.14%
ROE %23.13%
EPS1.76

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

no data available for Analyst Forecast

There's no data available for Analyst Forecast

Period: -

• Predicted: -

Analyst Ratings

no data available for Analyst Ratings

There's no data available for Analyst Ratings

Last updated: -

• Total: -

About Exelixis (EXEL)

Exelixis Inc (EXEL) is a biopharmaceutical company that specializes in the discovery, development, and commercialization of therapies for the treatment of cancer. With a strong focus on precision medicine and targeted therapies, Exelixis has established itself as a leader in the field. The company's flagship product, Cabometyx, is approved for the treatment of advanced renal cell carcinoma and hepatocellular carcinoma, two of the most common types of liver cancer. Cabometyx has shown significant efficacy and represents a breakthrough in the treatment of these diseases. In addition to Cabometyx, Exelixis has a robust pipeline of investigational compounds that target various types of cancer.
Exelixis Inc (EXEL) has a solid track record of financial performance and has consistently delivered strong revenue growth. The company's revenue has grown at a compound annual growth rate of over 40% in the past five years. This impressive growth can be attributed to the successful commercialization of Cabometyx and the high demand for targeted cancer therapies. Exelixis has also been able to maintain a strong balance sheet, with a healthy cash position and minimal debt. This financial stability provides the company with the resources needed to continue investing in research and development and drive future growth.
Show more
Websitecall_made
Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Michael M. Morrissey Ph.D.
Headquarters
Alameda
Employees
1223
Exchange
NASDAQ
add Exelixis to watchlist

Keep an eye on Exelixis

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help

What is Exelixis 's (EXEL) price per share?

The current price per share for Exelixis (EXEL) is $36.8. The stock has seen a price change of -$0.4 recently, indicating a -1.08% change. This reflects the stock's recent market performance and investor sentiment.
help

What is the 52-week high and low for Exelixis (EXEL)?

For Exelixis (EXEL), the 52-week high is $40, which is 8.69% from the current price. The 52-week low is $18.64, the current price is 97.42% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.
help

Is Exelixis (EXEL) a growth stock?

Exelixis (EXEL) has shown an average price growth of -1.65% over the past three years. It has received a score of 82 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Exelixis as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.
help

What is Exelixis (EXEL) stock price performance year to date (YTD)?

As of the latest data, Exelixis (EXEL) has a year-to-date price change of 10.51%. Over the past month, the stock has experienced a price change of 6.7%. Over the last three months, the change has been 5.05%. Over the past six months, the figure is 39.08%. Looking at a longer horizon, the five-year price change stands at 119.44%.
help

Is Exelixis (EXEL) a profitable company?

Exelixis (EXEL) has a net income of $521.27M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of 28.84% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $2.17B, with a revenue growth rate of 18.49%, providing insight into the company's sales performance and growth. The gross profit is $2.17B. Operating income is noted at $604.62M. Furthermore, the EBITDA is $804.08M.
help

What is the market capitalization of Exelixis (EXEL)?

Exelixis (EXEL) has a market capitalization of $10.3B. The average daily trading volume is 37.04, indicating the stock's liquidity and investor engagement.

Take Your Investments to a Whole New Level